Tumor Necrosis Factor Inhibitors Market Investigated by Kuick Research in New Topical Study Recently Uploaded at MarketPublishers.com
13 Jan 2017 • by Natalie Aster
LONDON – The anti- tumor necrosis factor (TNF) drugs are amid the top ten global block buster drugs, which have taken lead in the world’s pharmaceutical market landscape for any years.
For instance, in 2015 the combined sales of anti TNF drugs for rheumatic disease reached over USD 30 billion.
At present, there are 151 tumor necrosis factor inhibitors in the clinical pipeline, whilst 25 tumor necrosis factor inhibitors are commercially available in the market.
During the past decade, the pharmaceutical agents directed against TNF (for example adalimumab, infliximab and Etanercept) have been extensive and successfully used for the management of ankylosing spondylitis (AS), rheumatoid arthritis (RA), psoriatic arthritis, psoriasis, inflammatory bowel disease, among others.
Recently, two agents, namely certolimumab pegol and golimumab, entered the market for treatment of AS, RA, psoriasis and Crohn’s disease.
New topical report “Tumor Necrosis Factor Inhibitors Market & Clinical Pipeline Outlook 2022” prepared by Kuick Research presents a comprehensive analysis of the ongoing and non-clinical trends in the world’s tumor necrosis factor inhibitors market. This report highlights various approaches used in the development of anti TNF drugs and examines the function of tumor necrosis factor in neurodegenerative disorders, immune medicated inflammatory diseases and also development of cancer. It contains data on top trends, products in pipeline as well as marketed products, and also discusses hottest related issues. The report presents tumor necrosis factor inhibitors pipeline assessment by indication, company and phase. Furthermore, future forecasts are available.
More reports by this publisher are offered at the Kuick Research page.